Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Camp4 Therapeutics Corp (CAMP)

CAMP4 Therapeutics outlines ASCEND trial plans for CMP-002 in SYNGAP1 disorder

Neutral Impact 3 of 5 product/contract Written later

At an Analyst Day on September 28, 2026, CAMP4 Therapeutics described the design and timing of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder and gave a pipeline update. The company expects to dose the first patient by the end of 2026 and targets topline data in the first half of 2028, so the update sets out timelines but reports no clinical results or financial figures.

Key points

  • The company expects to dose the first patient in the ASCEND trial by the end of 2026 and targets topline data in the first half of 2028.
  • The trial plans three multiple ascending dose cohorts with a minimum of eight participants each, randomized 3:1 to intrathecal CMP-002 or a sham procedure.
  • The company expects to designate a development candidate in its SHANK3 program for Phelan-McDermid Syndrome in 2027, citing more than 45,000 US patients.

The filing

CompanyCamp4 Therapeutics Corp (CAMP)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:47 PM ET
Accession number0001628280-26-063740

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.